康莱特注射液辅助治疗复发性高级别脑胶质瘤的临床观察  

Clinical Observation of Kanglaite Injection in Adjuvant Treatment of Recurrent High-grade Brain Glioma

作　　者：潘玲 税典奎 张翠芳 胡国昌 傅彩霞 PAN Ling;SHUI Diankui;ZHANG Cuifang;HU Guochang;FU Caixia(Department of Oncology,Guilin Municipal Hospital of Traditional Chinese Medicine,Guilin 541002,China;Department of Gastroenterology,Liuzhou Traditional Chinese Medical Hospital,Liuzhou 545000,China)

机构地区：[1]桂林市中医医院肿瘤科,桂林541002 [2]柳州市中医医院消化科,柳州545000

出　　处：《世界中医药》2023年第24期3551-3555,共5页World Chinese Medicine

基　　金：广西自然科学基金项目(2019JJA140163)。

摘　　要：目的:观察康莱特注射液对复发性高级别脑胶质瘤患者免疫功能的影响。方法:选取2018年4月至2022年4月桂林市中医医院收治的复发性高级别脑胶质瘤患者90例作为研究对象,按照简单随机化法随机分为对照组和观察组,每组45例,对照组患者给予替莫唑胺治疗,观察组在对照组基础上加用康莱特注射液,比较2组患者治疗前后血常规指标、免疫功能相关指标、生命质量评分、临床疗效,以及不良反应。结果:对照组脱落2例,观察组脱落1例。治疗后,2组患者白细胞计数(WBC)、中性粒细胞(NE)、血小板计数(PLT)、血红蛋白(Hb)降低,观察组WBC、NE、PLT、Hb高于对照组(均P<0.05);对照组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)降低,CD8^(+)升高(均P<0.05),观察组均无明显变化,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组(均P<0.05);2组卡诺夫斯凯计分(KPS)、生命质量(QOL)评分升高,观察组KPS、QOL高于对照组(均P<0.05);观察组治疗有效率(90.91%,40/44)高于对照组(74.42%,32/43)(P<0.05)。2组均无严重不良反应发生。结论:复发性高级别脑胶质瘤化疗过程中联合康莱特注射液治疗,可以增加疗效,改善血常规,提高患者免疫功能和生命质量。Objective:To observe the effect of Kanglaite Injection on immune function in the patients with recurrent high-grade brain glioma.Methods:Ninety cases with recurrent high-grade brain glioma treated in the Guilin Municipal Hospital of Traditional Chinese Medicine from April 2018 to April 2022 were randomized into a control group(n=45,temozolomide)and an observation group(n=45,temozolomide+Kanglaite Injection).Blood routine,immune function,quality of life(QOL),efficacy,and adverse reactions were compared between the two groups.Results:Since two cases in the control group and one in the observation group dropped out,43 cases in the control group and 44 cases in the observation group were included for analysis.After treatment,the white blood cell count(WBC),neutrophil count(NE),platelet count(PLT),and hemoglobin(Hb)in the two groups decreased,and the WBC,NE,PLT,and Hb in the observation group were higher than those in the control group(P<0.05).After treatment,the control group showed decreased CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)and increased CD8^(+)(P<0.05),while the observation group showed no significant changes in the indicators above.Moreover,CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group after treatment(P<0.05).After treatment,the Kanofsky performance scale(KPS)and QOL scores increased in both groups,and KPS and QOL scores in the observation group were higher than those in the control group(P<0.05).The response rate in the observation group was 90.91%(40/44),which was higher than that(74.42%,32/43)in the control group(P<0.05).Neither group showed serious adverse reactions.Conclusion:In the course of chemotherapy for recurrent high-grade brain glioma,Kanglaite Injection can improve the therapeutic effect,blood routine,immune function,and quality of life.

关 键 词：复发 高级别脑胶质瘤 康莱特注射液 化疗 替莫唑胺 血常规 免疫功能 生命质量 

分 类 号：R273[医药卫生—中西医结合]